RxDoctor Payments Data

Cheryl Wideman, NP

Nurse Practitioner · Galena, AKNPI 1215301981

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $634 and has fallen 94.0% since, to $38 in 2024.

$717in general payments, 2019–2025

Across 36 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$165
  • AbbVie$124
  • Otsuka America Pharmaceutical, Inc.$102
  • Lilly USA, LLC$73
  • AstraZeneca$55
  • GSK$48
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$717 in reported general payments places this provider in the 80th percentile of 212 nurse practitioner providers in Alaska.

See all nurse practitioner providers in Alaska

Medicare billing

Part B allowed, 2024
$4,644
Medicare patients
49
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,060
MounjaroTirzepatide16$18,474
XareltoRivaroxaban25$14,505
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,314
FarxigaDapagliflozin Propanediol17$9,880
Atorvastatin Calcium71$858
Pantoprazole Sodium47$789
Sildenafil Citrate11$733
Omeprazole42$674
Albuterol Sulfate HfaAlbuterol Sulfate27$576
Rosuvastatin Calcium31$572
Potassium Chloride29$572
Hydralazine Hcl16$548
Carvedilol29$532
Amlodipine Besylate87$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$48$24,06029 claims
AstraZenecaBreztri Aerosphere, Farxiga$55$20,19433 claims
Lilly USA, LLCMounjaro$73$18,47416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 212 nurse practitioner providers in Alaska.

Other nurse practitioner in Galena

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →